Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity

European Journal of Cancer

Volumn 49, Issue 15, 2013, Pages 3353-3365

  Amaro, Adriana ^a   Mirisola, Valentina ^a   Angelini, Giovanna ^a   Musso, Alessandra ^a   Tosetti, Francesca ^a   Esposito, Alessia I ^a   Perri, Patrizia ^a   Lanza, Francesco ^b   Nasciuti, Francesca ^b   Mosci, Carlo ^b   Puzone, Roberto ^a   Salvi, Sandra ^a   Truini, Mauro ^a   Poggi, Alessandro ^a   Pfeffer, Ulrich ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b GALLIERA HOSPITAL   (Italy)

Author keywords

Antibody dependent cellular cytotoxicity; Epidermal growth factor receptor; Targeted therapy; Tyrosine kinase

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STIMULATION; CHROMOSOME 7P; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRISOMY; UVEA MELANOMA; WESTERN BLOTTING;

ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY; EPIDERMAL GROWTH FACTOR RECEPTOR; TARGETED THERAPY; TYROSINE KINASE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MELANOMA; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTOME; UVEAL NEOPLASMS;

EID: 84884909915     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.011     Document Type: Article

References (64)

1. M. Zeschnigk, and D.R. Lohmann Prognostic testing in uveal melanoma U. Pfeffer, Cancer genomics: molecular classification, prognosis and response prediction 2013 Springer Science and Business Media Dordrecht 79 96
2. C.D. Van Raamsdonk, K.G. Griewank, and M.B. Crosby Mutations in GNA11 in uveal melanoma N Engl J Med 363 23 2010 2191 2199
3. C.D. Van Raamsdonk, V. Bezrookove, and G. Green Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi Nature 457 7229 2009 599 602
4. J.W. Harbour, M.D. Onken, and E.D. Roberson Frequent mutation of BAP1 in metastasizing uveal melanomas Science 330 6009 2010 1410 1413
5. I.W. McLean, L.E. Zimmerman, and R.M. Evans Reappraisal of Callender's spindle a type of malignant melanoma of choroid and ciliary body Am J Ophthalmol 86 4 1978 557 564
6. L. Desjardins, C. Levy-Gabriel, and L. Lumbroso-Lerouic Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research J Fr Ophtalmol 29 7 2006 741 749
7. G. Prescher, N. Bornfeld, H. Hirche, B. Horsthemke, K.H. Jockel, and R. Becher Prognostic implications of monosomy 3 in uveal melanoma Lancet 347 9010 1996 1222 1225
8. G. Prescher, N. Bornfeld, and R. Becher Two subclones in a case of uveal melanoma. Relevance of monosomy 3 and multiplication of chromosome 8q Cancer Genet Cytogenet 77 2 1994 144 146
9. B. Horsthemke, G. Prescher, N. Bornfeld, and R. Becher Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma Genes Chromosomes Cancer 4 3 1992 217 221
10. J.A. Metzelaar-Blok, M.J. Jager, P.H. Moghaddam, A.R. van der Slik, and M.J. Giphart Frequent loss of heterozygosity on chromosome 6p in uveal melanoma Hum Immunol 60 10 1999 962 969
11. R. Gangemi, V. Mirisola, and G. Barisione Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression PLoS One 7 1 2012 e29989
12. M.D. Onken, L.A. Worley, M.D. Tuscan, and J.W. Harbour An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma J Mol Diagn 12 4 2010 461 468
13. G. Virgili, G. Gatta, and L. Ciccolallo Survival in patients with uveal melanoma in Europe Arch Ophthalmol 126 10 2008 1413 1418
14. M.R. Middleton, J.J. Grob, and N. Aaronson Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 1 2000 158 166
15. J.J. Augsburger, Z.M. Correa, and A.H. Shaikh Effectiveness of treatments for metastatic uveal melanoma Am J Ophthalmol 148 1 2009 119 127
16. U.B. Hofmann, C.S. Kauczok-Vetter, R. Houben, and J.C. Becker Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate Clin Cancer Res 15 1 2009 324 329
17. M.H. Abdel-Rahman, E.L. Craig, F.H. Davidorf, and C. Eng Expression of vascular endothelial growth factor in uveal melanoma is independent of 6p21-region copy number Clin Cancer Res 11 1 2005 73 78
18. T.G. Sheidow, P.L. Hooper, C. Crukley, J. Young, and J.G. Heathcote Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis Br J Ophthalmol 84 7 2000 750 756
19. G. Lefevre, N. Babchia, and A. Calipel Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells Invest Ophthalmol Vis Sci 50 3 2009 1047 1057
20. P. Topcu-Yilmaz, H. Kiratli, A. Saglam, F. Soylemezoglu, and G. Hascelik Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma Melanoma Res 20 2 2010 126 132
21. K. Mallikarjuna, V. Pushparaj, J. Biswas, and S. Krishnakumar Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study Curr Eye Res 32 3 2007 281 290
22. D. Yan, X. Zhou, and X. Chen MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met Invest Ophthalmol Vis Sci 50 4 2009 1559 1565
23. K. Mallikarjuna, V. Pushparaj, J. Biswas, and S. Krishnakumar Expression of insulin-like growth factor receptor (IGF-1R), c-Fos, and c-Jun in uveal melanoma: an immunohistochemical study Curr Eye Res 31 10 2006 875 883
24. M.A. Economou, C. All-Ericsson, and V. Bykov Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications Invest Ophthalmol Vis Sci 46 12 2005 4372 4375
25. A.B. Daniels, J.E. Lee, and L.E. MacConaill High throughput mass spectrometry-based mutation profiling of primary uveal melanoma Invest Ophthalmol Vis Sci 53 11 2012 6991 6996
26. M. Schartl, B. Wilde, J.A. Laisney, Y. Taniguchi, S. Takeda, and S. Meierjohann A mutated EGFR is sufficient to induce malignant melanoma with genetic background-dependent histopathologies J Invest Dermatol 130 1 2010 249 258
27. D. Ma, and J.Y. Niederkorn Role of epidermal growth factor receptor in the metastasis of intraocular melanomas Invest Ophthalmol Vis Sci 39 7 1998 1067 1075
28. H.M. Hurks, J.A. Metzelaar-Blok, and E.R. Barthen Expression of epidermal growth factor receptor: risk factor in uveal melanoma Invest Ophthalmol Vis Sci 41 8 2000 2023 2027
29. A.G. Scholes, S. Hagan, P. Hiscott, B.E. Damato, and I. Grierson Overexpression of epidermal growth factor receptor restricted to macrophages in uveal melanoma Arch Ophthalmol 119 3 2001 373 377
30. J. Kan-Mitchell, M.S. Mitchell, N. Rao, and P.E. Liggett Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes Invest Ophthalmol Vis Sci 30 5 1989 829 834
31. I. De Waard-Siebinga, D.J. Blom, and M. Griffioen Establishment and characterization of an uveal-melanoma cell line Int J Cancer 62 2 1995 155 161
32. G.P. Luyten, N.C. Naus, and C.M. Mooy Establishment and characterization of primary and metastatic uveal melanoma cell lines Int J Cancer 66 3 1996 380 387
33. P.W. Chen, T.G. Murray, M.L. Salgaller, and B.R. Ksander Expression of MAGE genes in ocular melanoma cell lines J Immunother 20 4 1997 265 275
34. B.R. Ksander, P.E. Rubsamen, K.R. Olsen, S.W. Cousins, and J.W. Streilein Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma Invest Ophthalmol Vis Sci 32 13 1991 3198 3208
35. G. Nareyeck, M. Zeschnigk, G. Prescher, D.R. Lohmann, and G. Anastassiou Establishment and characterization of two uveal melanoma cell lines derived from tumors with loss of one chromosome 3 Exp Eye Res 83 4 2006 858 864
36. K.G. Griewank, X. Yu, and J. Khalili Genetic and molecular characterization of uveal melanoma cell lines Pigment Cell Melanoma Res 25 2 2012 182 187
37. R. Folberg, S.S. Kadkol, and S. Frenkel Authenticating cell lines in ophthalmic research laboratories Invest Ophthalmol Vis Sci 49 11 2008 4697 4701
38. V.G. Tusher, R. Tibshirani, and G. Chu Significance analysis of microarrays applied to the ionizing radiation response Proc Nat Acad Sci USA 98 9 2001 5116 5121
39. Y. Nannya, M. Sanada, and K. Nakazaki A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays Cancer Res 65 14 2005 6071 6079
40. T. Mukohara, J.A. Engelman, and N.H. Hanna Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations J Natl Cancer Inst 97 16 2005 1185 1194
41. M.S. Cragg, J. Kuroda, H. Puthalakath, D.C. Huang, and A. Strasser Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics PLoS Med 4 10 2007 1681 1689 discussion 1690
42. B.E. Bachmeier, C.M. Iancu, and P.H. Killian Overexpression of the ATP binding cassette gene ABCA1 determines resistance to Curcumin in M14 melanoma cells Mol Cancer 8 2009 129
43. C. Delbaldo, J.Y. Pierga, and V. Dieras Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma Eur J Cancer 41 12 2005 1739 1745
44. F.R. Luo, Z. Yang, and H. Dong Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model Clin Cancer Res 11 15 2005 5558 5565
45. M.R. Zocchi, S. Catellani, and P. Canevali High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas Blood 119 6 2012 1479 1489
46. A. Citri, and Y. Yarden EGF-ERBB signalling: towards the systems level Nat Rev Mol Cell Biol 7 7 2006 505 516
47. X. Wu, M. Zhu, J.A. Fletcher, A. Giobbie-Hurder, and F.S. Hodi The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma PLoS One 7 1 2012 e29622
48. R. Danielli, R. Ridolfi, and V. Chiarion-Sileni Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy Cancer Immunol Immunother 61 1 2012 41 48
49. M.H. Abdel-Rahman, G. Boru, J. Massengill, M.M. Salem, and F.H. Davidorf MET oncogene inhibition as a potential target of therapy for uveal melanomas Invest Ophthalmol Vis Sci 51 7 2010 3333 3339
50. S. Landreville, O.A. Agapova, and K.A. Matatall Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma Clin Cancer Res 18 2 2012 408 416
51. R. Perez-Soler, A. Chachoua, and L.A. Hammond Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 16 2004 3238 3247
52. J.G. Paez, P.A. Janne, and J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 5676 2004 1497 1500
53. J.D. Sato, T. Kawamoto, A.D. Le, J. Mendelsohn, J. Polikoff, and G.H. Sato Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors Mol Biol Med 1 5 1983 511 529
54. T. Yoshida, I. Okamoto, and T. Okabe Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk Int J Cancer 122 7 2008 1530 1538
55. T. Matsuo, S.S. Nishizuka, K. Ishida, T. Iwaya, M. Ikeda, and G. Wakabayashi Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models BMC Res Notes 4 2011 140
56. K.R. Schmitz, and K.M. Ferguson Interaction of antibodies with ErbB receptor extracellular regions Exp Cell Res 315 4 2009 659 670
57. A. Lopez-Albaitero, S.C. Lee, and S. Morgan Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells Cancer Immunol Immunother 58 11 2009 1853 1864
58. A.J. Weickhardt, T.J. Price, and G. Chong Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer J Clin Oncol 30 13 2012 1505 1512
59. V. Damiano, R. Caputo, and S. Garofalo TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts Proc Nat Acad Sci USA 104 30 2007 12468 12473
60. A.C. Repp, E.S. Mayhew, S. Apte, and J.Y. Niederkorn Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells J Immunol 165 2 2000 710 715
61. J.Y. Niederkorn Immunoregulation of intraocular tumours Eye 11 Pt 2 1997 249 254
62. W. Zhang, M. Gordon, and A.M. Schultheis FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab J Clin Oncol 25 24 2007 3712 3718
63. F. Bibeau, E. Lopez-Crapez, and F. Di Fiore Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan J Clin Oncol 27 7 2009 1122 1129
64. M.B. Overdijk, S. Verploegen, and J.H. van den Brakel Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition J Immunol 187 6 2011 3383 3390